Kornimate/medical-research-clean huggingface dataset:
analyzing the pharmacodynamic substances and the effects of xingnaojing for mild-to-severe acute ischemic stroke

Conditions: Ischemic Stroke, Acute

Summary: the main purposes of this trial are to analyze the pharmacodynamic substances and the effects of xingnaojing for mild-to-severe acute ischemic stroke.

xingnaojing is widely used in china, but there is lack of sufficient and reasonable explanation of its intervention effects for acute ischemic stroke currently. in order to further clarify the main pharmacodynamic substances of xingnaojing in the treatment of acute ischemic stroke, this study intends to carry out a non-randomized, open-label, controlled clinical trial. the primary hypothesis is that , compared with the control group, xingnaojing will produce serial changes in plasma metabolites at baseline (pre-dose) and 7 days, as well as urine metabolites at baseline (pre-dose), 6 days, 7 days and 8 days. the serial changes may be the potential support to explain the intervention effect of xingnaojing. all participants will have a national institutes of health stroke scale(nihss)entry score of 4-25. participants who have planned or already received the intravenous thrombolysis or endovascular treatment will be excluded.

Eligibility criteria:
inclusion criteria: * diagnosis of acute ischemic stroke； * symptom onset within 24 hours； * 40 ≤ age ≤ 80 years; * 4 ≤ nihss ≤ 25； * patient or legally authorized representative has signed informed consent. exclusion criteria: * planned or already receiving intravenous thrombolysis or endovascular treatment; * suspected secondary stroke caused by tumor, brain trauma, or hematological diseases; * already dependent in activities of daily living before the present acute stroke (defined as modified rankin scale score ≥ 2) ; * other conditions that cause cardiogenic embolism (e.g., atrial fibrillation, rheumatic heart disease, valvular heart disease); * other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis); * significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase (alt), or aspartate aminotransferase (ast) value that is twice the upper limit of normal); * life expectancy of 3 months or less due to other life-threatening illness (e.g.,advanced cancer) * other conditions that render outcomes or follow-up unlikely to be assessed; * known to be pregnant or breastfeeding; * use any drugs containing traditional chinese medicine within 1 week before enrollment; * currently receiving an investigational drug.
efficacy study of cpap on nitrate and norepinephrine levels in severe and mild-moderate sleep apnea (sabio)

Conditions: Obstructive Sleep Apnea

Summary: reduced plasma nitrate (nox) levels and increased urinary norepinephrine (u-ne) levels have been described in severe obstructive sleep apnea (osa), and are reverted by continuous positive airway pressure (cpap). the investigators wanted to know the effect of cpap on these biomarkers in mild-moderate osa.

the investigators aimed to compare nox and u-ne levels and blood pressure (bp) between male patients with mild-moderate and severe osa and determine the impact of 1 month of cpap therapy on these parameters. the investigators undertook a prospective study of 67 consecutive osa patients (36 mild-moderate, 31 severe). measurements of plasma nox at 11 pm, 4 am and 7 am, 24-h u-ne and ambulatory bp were obtained at baseline and after 1 month of cpap.

Eligibility criteria:
inclusion criteria: - diagnosis of obstructive sleep apnea exclusion criteria: * current smoker * respiratory disease * cardiac disease (except for arterial hypertension) * renal disorder * hepatic disorder * psychiatric disorder * diabetes mellitus * dyslipidemia * rhinitis * sinusitis * acute illness * daytime hypoxemia or hypercapnia * therapy with oral nitrates * therapy with angiotensin-converting enzyme inhibitors * therapy with beta-blockers * therapy with statins * therapy with non-steroidal anti-inflammatory drugs * presence of central respiratory events * previous cpap therapy * previous uvulopalatopharyngoplasty

Keywords: sleep apnea cpap treatment plasma nitrate urinary norepinephrine blood pressure
phase ii evaluation of low-dose oral etoposide for the treatment of relapsed or progressed aids-related kaposi's sarcoma after systemic chemotherapy

Conditions: Sarcoma, Kaposi; HIV Infections

Summary: to assess the toxicity, tumor response rate, and effect on quality of life of daily low-dose etoposide administered for 7 consecutive days every other week in patients with aids-related kaposi's sarcoma that has relapsed or progressed after systemic chemotherapy. etoposide may be at least as, or even more, effective and less myelotoxic when given in low doses over prolonged periods of time.

etoposide may be at least as, or even more, effective and less myelotoxic when given in low doses over prolonged periods of time. patients receive low-dose oral etoposide on days 1 through 7 of every 2-week cycle. patients who achieve a complete or partial response after two cycles and have no toxicity greater than grade 2 may have their dose escalated for subsequent cycles. if there are no responses to therapy among the first 14 evaluable patients, the study will close; if there is at least one objective response to therapy among the first 14 evaluable patients, enrollment will continue until all 41 patients are enrolled. patients continue therapy until maximal tumor response (either stable disease or complete response) is achieved or disease progression occurs.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * maintenance therapy for opportunistic infections. patients must have: * hiv infection. * kaposi's sarcoma that has relapsed or progressed. * mucocutaneous lesions (15 or more) and/or symptomatic mucosal lesions and/or visceral kaposi's sarcoma (symptomatic lymphedema qualifies patients in the absence of these three conditions). * no active acute opportunistic infections requiring treatment with myelosuppressive antibiotics (maintenance for ois is permitted). * consent of parent or guardian if less than 18 years of age. note: * this study is approved for prisoner participation. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * other active malignancies except basal cell carcinoma of the skin, or carcinoma in situ of the cervix. * grade 3 or worse peripheral neuropathy. * altered mental status that would prevent informed consent or prevent study compliance. patients with the following prior condition are excluded: neuropsychiatric history. prior medication: excluded: * prior etoposide. * any other anti-ks drugs within 14 days prior to study entry. * any investigational drug other than antiretrovirals within 14 days prior to study entry. * any prior investigational agent, if given as the only prior treatment for ks. prior treatment: excluded: * radiation therapy within 7 days prior to study entry. continued alcohol consumption or continued intravenous drug use that would impair ability to comply with study requirements.

Keywords: sarcoma, kaposi etoposide acquired immunodeficiency syndrome
the relationship between gbs screening in pregnant women insured in maccabi healthcare services (mhs) and early-onset neonatal disease in israel

Conditions: Streptococcal Infection Group B as Cause of Diseases Classified Elsewhere (Diagnosis)

Summary: determination of gbs colonization rates in pregnant women insured with maccabi health services, doctors' compliance rates for referral for testing, test execution rates, and early-onset gbs disease (eogbsd) rates in israel. determine the relationship between conducting a gbs test in pregnant women and eogbsd in israel.

there have been few studies in recent years, which has prompted us to undertake this study. our aim was to examine the current colonization rates and attack rates in the israeli population. our secondary aim was to evaluate the need to readjust recommendations towards universal screening.

Eligibility criteria:
inclusion criteria: * all women with term pregnancies from 2015 to 2016 (until 20/9/16) insured by maccabi healthcare services (mhs) exclusion criteria: * repeat pregnancies occurring in the same woman during the time period * multiple pregnancies * gestational age greater than 42 weeks due to probability of data inaccuracy * women with missing information
effect of light-emitting diode (led) photobiomodulation therapy on muscular fatigue in university handball athletes

Conditions: Muscular Injury

Summary: introduction: low-intensity laser therapy (lbi) is a therapeutic modality with a large number of clinical studies in recent years, taking into account its effectiveness in tissue repair, pain control and, more recently, to increase performance. it is known that led therapy has immediate effects. therefore, analyzing the tled in the infrared spectrum for acute responses at different times along with fatigue resistance capabilities, heart rate variability and biochemical response to fatigue in handball athletes becomes necessary. objective: to analyze the acute effects of led phototherapy (940nm) on fatigue resistance and recovery after strenuous exercises of university athletes. method: the study sample will consist of 32 and 36 male athletes, for biceps brachii and quadriceps femoris, respectively. the athletes will be randomly assigned into four groups: immediate tled (tled-i), tled 15min (tled-15), immediate sham (sham-i) and sham 15min (sham-15). the tests performed will involve bioimpedance evaluation, blood lactate, electromyographic analysis and evaluation of maximum voluntary contraction by means of the maximal repetition test (1rm). thus, the tled will be applied on the muscle group to be evaluated, unilaterally, the same tests being repeated in the sequence. for analysis of the data, normality test will be used to verify the distribution and adequate statistical tests for the appropriate intra and intergroup comparisons, being considered two factors in the comparisons, time and group. a significance level of 5% will be adopted.

it is a blinded randomized clinical trial. the athletes will undergo a previous evaluation (day 1) comprised by anamnesis and evaluation of the bioimpedance to analyze the body composition, will still carry out the evaluation of the load for a maximum repetition. thus, 7 days after (day 2) the previous evaluation in the times immediately after and after 15 minutes of the led application will be carried out new tests. these will involve assessment of blood lactate, heart rate variability and electromyography. in addition, during the execution of the fatigue protocol will be collected the number of repetitions of muscle contraction and its total execution time. due to the number of athletes that make up the university team (n = 19), cross-over will be necessary, where all athletes will initially be distributed to the 04 pre-defined groups in each subproject, and after the 7 days, they will be divided again.

Eligibility criteria:
inclusion criteria: * handball practitioners; * absence of musculoskeletal injury in the last three months; * absence of anti-inflammatory and / or analgesic drugs 72 hours before the evaluations exclusion criteria: * use of anabolic steroids; * presence of cardiovascular disease * use of alcohol and illicit drugs during the collection period

Keywords: physiotherapy muscle resistance led athletic performance
quantification of cerebral blood flow by arterial spin labeling in vasospasm in subarachnoid haemorrhage

Conditions: Subarachnoid Hemorrhage

Summary: a technique of mri infusion -l'arterial spin labeling-, non-invasive and non-irradiating, repeatable over time, appears promising in the field. this sequence allows for routine, generate perfusion maps relating to the entire brain volume

the subarachnoid hemorrhage (sah) is a relatively severe disease whose prognosis is particularly related to the early onset of arterial vasospasm, maximum between the 5th and 14th day after sah. many obstacles make it difficult screening and monitoring of such complication. the challenge is to be able to demonstrate a reduction in regional cerebral blood flow before the onset of irreversible parenchymal sequelae, responsible for the majority of long-term morbidity among survivors. in clinical routine, screening vasospasm is achieved by doppler intracranial arteries (dtc). however, its sensitivity is poor with regard to the middle and anterior cerebral arteries. the gold standard for diagnosis is cerebral arteriography. however, vasospasm in arteriography or trans-cranial doppler does not prejudice the appearance of a delayed ischemic deficit. a technique of mri infusion -l'arterial spin labeling-, non-invasive and non-irradiating, repeatable over time, appears promising in the field. this sequence allows for routine, generate perfusion maps relating to the entire brain volume

Eligibility criteria:
inclusion criteria: * adults. * who have given their written consent. * affiliated to a social security system. * any patient hospitalized at the university hospital of angers in neurosurgical intensive care unit for supervision by asl and dtc a subarachnoid hemorrhage from all etiologies (excluding traumatic). exclusion criteria: * contraindications to mri * patient hospitalized at the university hospital of angers in surgical intensive care for monitoring a subarachnoid hemorrhage. * patient hospitalized at the university hospital of angers for monitoring a subarachnoid hemorrhage traumatic.
adjuvant treatment in extensive unilateral retinoblastoma primary enucleated (rb sfce 2009)

Conditions: Retinoblastoma

Summary: postoperative treatment of unilateral retinoblastoma after primary enucleation according to histopathological risk factors of the international retinoblastoma staging working group.

post operative chemotherapy +/- radiotherapy according to histopathological risk factors of the international retinoblastoma staging working group. * low risk group : * no optic nerve involvement. * intra and prelaminar involvement * no choroidal involvement. * minimal superficial choroidal involvement . * intermediate risk group, 2 sub groups : * sub group 1 : * retrolaminar involvement without invasion of surgical margin associated or not to massive choroidal involvement * anterior segment involvement. * intrascleral involvement. * sub group 2 : * isolated massive choroidal involvement. * high risk group : * invasion of the surgical margin of the optic nerve * and/or microscopic extrascleral involvement * optic nerve meningeal sheat involvement .

Eligibility criteria:
inclusion criteria: 1. written informed consent - a signed informed consent and/or assent (as age appropriate) will be obtained according to institutional guidelines; 2. male or female ≥2 months and \<10 years of age at the time of signing the informed consent form; 3. diagnosis of non familial extensive unilateral retinoblastoma treated by primary enucleation 4. in case of post operative chemotherapy, patients must have adequate organ function: * adequate hematopoietic function neutrophils\>1.0x109/l, platelets \>100 x 109/l. * adequate hepatic function: grade ii nci ctc * adequate renal function: serum creatinemia \<1.5 x uln for age with normal creatinine clearance estimated by schwartz formula * audiometry \< grade ii de brock. * echocardiography normal in case of high dose cyclophosphamide chemotherapy (3 g/m²). 5. patients affiliated to a social security regimen or beneficiary of the same 6. no chemotherapy or radiotherapy prior to administration of the first dose of study treatment for retinoblastoma or other tumor types 7. without medical cons-indication to study drugs. exclusion criteria: * bilateral and/or familial or trilateral retinoblastoma. * unilateral retinoblastoma with indication of primary chemotherapy before enucleation: * one or several surgical risk factors * buphthalmia exophthalmia. * peri ocular inflammatory signs. * extraocular extension : * radiological retrolaminar extension (more than 3 mm behind the lamina cribrosa) and or meningeal sheat optic nerve extension. * extrascleral extension * lymp nodes extension * unilateral retinoblastoma with possibility of conservative treatment: * metastatic extension at diagnosis * one inclusion criteria non observed * uncontrolled medical conditions, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

Keywords: primary enucleation retinoblastoma
detection of amplification of her2 fluorescent in situ hybridization (fish) in breast tissue sections

Conditions: Breast Cancer

Summary: the purpose of the study is the identification of amplification level in human breast tissue. the imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of her2 fish stained tissue samples.


Eligibility criteria:
inclusion criteria: * well stained breast tissue slides with bright her2 signals exclusion criteria: * very old slides that were already bleached

Keywords: her2 fish breast cancer amplification
quantitative analysis of different acupuncture needle manipulation to treat chronic shoulder pain

Conditions: Shoulder Pain

Summary: the plan " quantitative analysis of different acupuncture needle manipulation to treat chronic shoulder pain "includes an objective observation of acupuncture operation (movement in the form of acupuncture needles, intensity, etc.) and the body (acupoints) reactions. patients during 20-55 years old suffered shoulder pain more than six weeks with numerical rating scale (nrs) pain intensity more than 5 points, and the previous month were not taking medicine or western medicine were included. then use of distal acupoints gb34 and gb39, giving once acupuncture manipulation therapy.

numerical rating scale (nrs) and pain pressure algometer were used to objective and quantitative assessment of the patient's pain. and shoulder pain and disability index-spadi was used to objectively assess the functional changes of acupuncture treatment in patients with chronic shoulder pain. massachusetts general hospital acupuncture sensation scale - mass was used to get objectively record of de-qi when needle manipulation for the the body (acupoints) reactions. acusensor2 was used to get objective observation reaction during needling manipulation, the sensor provided measurement parameters such as the lift and thrust, twisting, strength and torque during needle manipulation. investigators will study and analysis associated clinical outcome with needling process, the needle manipulation by lifting-thrusting or twisting-rotating during the process of reinforce method or reducing method to study its dynamics and kinematics.

Eligibility criteria:
inclusion criteria: * (a) have agreed to participate in the trial and signed by the chang geng memorial hospital human body test committee approved the human test consent. * (b) suffering from chronic shoulder pain (including frozen shoulder, or rotator cuff injury, or subclavian bursitis, or biceps tendonitis or nonspecific shoulder pain). * (c) at least six weeks before the screening period of shoulder pain, digital grading scale measurement of pain intensity of 5 points or more. exclusion criteria: * (a) shoulder fracture * (b) intra-articular infection * (c) stroke hemiplegia * (d) spinal cord injury * (e) postoperative shoulder surgery * (f) pregnant woman, * (g) took traditional chinese medicine or western medicine, less than one month before the screening period
ivb for post-vitrectomy hemorrhage in diabetic eyes

Conditions: Diabetic Retinopathy; Vitreous Hemorrhage

Summary: recurrent vitreous hemorrhage following pars plana vitrectomy (ppv) for proliferative diabetic retinopathy remains a significant complication with reported incidence ranging from 11 to 75%. early and late recurrences are associated with various factors, including residual blood, fibrovascular tissue, and neovascularization. despite attempts to reduce this complication with therapies like anti-fibrinolytic agents, gas tamponade, and peripheral cryotherapy, the outcomes remain unsatisfactory.

recurrent vitreous hemorrhage following pars plana vitrectomy (ppv) for proliferative diabetic retinopathy remains a significant challenge with high incidence and negative impact on visual outcomes. despite various treatments, intravitreal bevacizumab (ivb) has shown potential in reducing post-operative vitreous hemorrhage (po-vh). this study aims to determine the efficacy and safety of intraoperative ivb in preventing po-vh in patients undergoing vitrectomy for diabetic vitreous hemorrhage. this prospective, randomized controlled trial compared patients receiving intraoperative ivb to a control group. the primary outcome was po-vh incidence at one month, with secondary outcomes including visual acuity change, time to vh clearance, and safety. outcome assessors were masked to the study treatment. data on demographics, medical history, visual acuity, vh grading, intraoperative findings, and postoperative complications will be collected. statistical analysis compared po-vh incidence and other outcomes between groups. this study will provide valuable evidence on the efficacy and safety of intraoperative ivb in preventing po-vh, contributing to improved clinical practice and patient outcomes.

Eligibility criteria:
inclusion criteria: * patients with spontaneous, non-clearing vitreous hemorrhage for at least one month as the initial vitrectomy indication for diabetic retinopathy. exclusion criteria: * patients with tractional retinal detachment (art) * patients with severe fibrovascular traction, * patients with intravitreal gas or silicone oil tamponade at the end of surgery * patients with other eye diseases besides diabetic vitreous hemorrhage * patients with history of intravitreal bevacizumab injection in the last 3 months before surgery * patients with other health condition includes uncontrolled hypertension, a history of coagulopathy * patients with inability to attend follow-up examinations for at least 1 month * patients taking anti-aggregation and anti-platelet medications with abnormal bleeding time (bt) and clotting time (ct)

Keywords: diabetic vitreous hemorrhage intravitreal bevacizumab pars plana vitrectomy proliferative diabetic retinopathy recurrent vitreous hemorrhage